|
Beth C. Seidenberg MD was appointed to the Board in December 2005. Dr. Seidenberg has served as Partner of Kleiner Perkins Caufield and Byers (KPCB) since May 2005. Prior to joining KPCB Dr. Seidenberg served as Amgen’s Chief Medical Officer and Senior Vice President Global Development from January 2002 to December 2004 at Bristol-Myers Squibb Company as Senior Vice President Global Development from September 2001 to January 2002 Senior Vice President Clinical Development & Life Cycle Management from May 2000 to September 2001 and Vice President Clinical Immunology/Pulmonary/Dermatology from April 2000 to May 2000 and at Merck/Merck Research Laboratories as Vice President Pulmonary-Immunology from July 1998 to March 2000 Executive Director from March 1996 to June 1998 Senior Director from September 1993 to February 1996 and also served as both Director and Associate Director of Clinical Pharmacology from September 1991 to August 1993 and from June 1989 to August 1991 respectively. She received her M.D. from University of Miami; completed post-doctoral training at Johns Hopkins Medical Center and specialty training in immunology and infectious diseases at the National Institutes of Health. Dr. Seidenberg also has a B.S. degree in Biology and Anthropology from Barnard College. Dr. Seidenberg was appointed to the Board as a designee of KPCB under a Nomination and Observer Agreement with the Company dated December 16 2005. | 